Core Viewpoint - The collaboration between Insilico Medicine and a global independent pharmaceutical company, Sviat, is valued at up to $888 million, focusing on the development of new cancer therapies using Insilico's AI platform, Pharma.AI [1] Group 1: Collaboration Details - The partnership will leverage Insilico's AI technology to identify and develop new drug candidates targeting challenging oncology areas [1] - Insilico is eligible for an upfront payment of up to $32 million and milestone payments related to recent R&D achievements [1] - Sviat will share the R&D costs and lead the subsequent clinical validation and commercialization processes [1] Group 2: Statements from Executives - Christophe Thurieau, Executive Director at Sviat, emphasized the commitment to using advanced technology to address unmet medical needs and benefit patients [1] - Alex Zhavoronkov, CEO of Insilico, expressed excitement about the collaboration, highlighting the recognition of the company's AI drug development capabilities [1] - Zhavoronkov also mentioned the potential for generative AI to enhance drug development processes, making them faster, smarter, and safer [1]
英硅智能与施维雅达成价值8.88亿美元的多年期抗肿瘤药物研发合作